Jenex Featured at www.WallStreetCorner.com

Thursday September 20, 2007

BURLINGTON, ON, Business Wire - THE JENEX CORPORATION (TSX Venture Exchange: JEN and Frankfurt: JNX), announced it has been featured in Larry Oakley’s Stock Pick editorial at www.WallStreetCorner.com.

Oakley said as part of his editorial: “I interviewed President Michael A. Jenkins and feel this company is a winner. After receiving samples of its main products, my enthusiasm has substantially increased. I really like the appreciation potential of this situation. The market is huge for both products. I like the fact that it is now entering its commercialization phase, a good time in my opinion to take a modest position, prior to the time the investing public understands the potential that exists here.”

He added: “You may be acquainted with Abreva. It’s advertised as the only non-prescription COLD SORE medicine approved by the FDA to shorten healing time & duration of symptoms. I have been told that GlaxoSmithKline (NYSE:GSK) … licensed Abreva for North America, in a five year deal that included $25 million in up-front fees and royalties to Avanir Pharmaceuticals. Abreva’s claim is to shorten duration. Jenex’s Non-invasive Medical Device called interceptCS™ actually prevents the cold sore from erupting!”

About The Jenex Corporation: Jenex has a Non-invasive Medical Device that prevents the eruption of “cold sores.” The interceptCS™ Cold Sore Prevention System is approved in Canada and received CE approval for European Union countries. Jenex also has a product called Therapik®. It could be described as “Sting No More.” It immediately relieves the pain & itch caused by stings & bites. It has FDA approval. Both products use Jenex’s Thermal Therapy (heat technology) that is patented in the U.S., Canada, Australia, & Europe. The company’s Mission statement:  “Inform and educate the public about our safe and effective products that have been clinically proven and approved to provide improved life style benefits." Vision statement:  "Commercialization of our patented product line allowing Jenex to be the pre-eminent leader in cold sore prevention and insect bite & sting relief." Jenex has the potential to dominate two huge underdeveloped markets. Check www.interceptCS.com and www.jenexcorp.com for details.

About WallStreetCorner.com: Formed eight years ago by Larry Oakley, known as the "Elder Statesman of Emerging Growth Company Writers," as a venue for his Conservative Speculator newsletter published since 1987, www.WallStreetCorner.com, including the corporate profiles of its participants, Conservative Speculator, and Oakley's "Stock Pick," "Opinion,"  “Comment,” "Bold Ventures," and "Economic Comments" editorial columns, is now regularly read by investors in 93 countries.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

Contact: Michael A. Jenkins, President,

Phone: 905-632-3830

Email: jenex@jenexcorp.com

Website: www.JenexCorp.com